ZyVersa Therapeutics (NASDAQ:ZVSA) has highlighted data from a peer-reviewed International Journal of Nanomedicine article demonstrating inflammasome inhibition’s potential to protect pancreatic islet beta cells and slow the progression from obesity to insulin resistance and Type 2 diabetes. Data from the article support ZyVersa’s development of the Inflammasome ASC Inhibitor IC 100 for obesity and its associated comorbidities, to be used as an add-on to incretin therapy.
In the article, researchers revealed findings from their investigation into how exosomes derived from gut microbiota can transport signals to remotely regulate pancreatic islet β-cell function.
“This data supports the potential of Inflammasome ASC Inhibitor IC 100, as a key component of obesity care when added to incretins used for weight loss. According to the International Obesity Collaborative, obesity care is about health, not weight. It consists of evidence-based options that address the comorbidities of obesity, such as diabetes, hypertension, and hyperlipidemia, and improve well-being,” said Stephen C. Glover, co-founder, chairman, CEO, and president of ZyVersa.
“We are excited about the potential of IC 100 to effectively control the inflammation of obesity. Unlike the NLRP3 inhibitors in development, IC 100 targets ASC to inhibit multiple inflammasomes, including NLRP3 and AIM2, which are activated in obesity. More importantly, IC 100 uniquely disrupts the function of ASC specks to attenuate the chronic, systemic inflammation leading to obesity comorbidities. We look forward to progressing IC 100’s obesity development program into phase 1 around mid-2025,” Mr. Glover added.
